UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K/A
 
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  April 11, 2017

INVO BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)
 
Nevada
 
333-147330
 
20-4036208
(State or other jurisdiction of
 
(Commission
 
(I.R.S. Employer
Incorporation)
 
File Number)
 
Identification No.)

407R Mystic Avenue, Suite 34C, Medford, MA   02155
(Address of principal executive offices)          (Zip Code)

(978) 878-9505
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
     
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
 
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 FR 240.13e-4(c))
 



EXPLANATORY NOTE

INVO Bioscience, Inc. (the “Company”) is furnishing this Amendment No. 1 to its Current Report on Form 8-K (“Amendment No. 1”) furnished with the SEC on April 10, 2017 (the “Original Form 8- K”), pursuant to Item 5.02(a)(3)(iii) which requires the Company to file any letter received from the director.  Attached is the letter INVO Bioscience received.

Item 9.01
Financial Statements and Exhibits
 
Exhibit Number
 
Description
17.1
 




SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
INVO Bioscience, Inc.
 
 
 
 
 
Date: April 13, 2017 
By:
/s/ Kathleen T. Karloff         
 
 
 
Kathleen T. Karloff
 
 
 
Chief Executive Officer and Chairman of the Board of Directors